

Division of Medical Assistance (DMA) Perspective on 17P

April 27, 2011

- The Division continues to support the use of 17P (hydroxyprogesterone caproate) in the pregnancy home to prevent preterm labor. The Division encourages providers to rely on their prior success with compounded 17P when making decisions for their patients.
- The Division will continue to reimburse providers for compounded 17P through the Physician's Drug Program.
 - The practice obtains a vial of 17P from a compounding pharmacy, pays the pharmacy for the 17P, then submits a claim to Medicaid for each dose administered. 17P can be purchased in 10-dose, 5-dose or single-dose vials. The claim can be submitted electronically using the unlisted drug code J3490, diagnosis code V23.41, the NDC number from the medication, and the NDC units. Compounded 17P cannot be billed through the Outpatient Pharmacy Program at point-of-sale; therefore, patients should not be given a prescription for compounded 17P to take to a pharmacy.
 - The FDA has announced "that it does not intend to take enforcement action against pharmacies that compound hydroxyprogesterone caproate based on a valid prescription for an individually identified patient unless the compounded products are unsafe, of substandard quality, or are not being compounded in accordance with appropriate standards for compounding sterile products."¹
- Medicaid will also cover MakenaTM through the Physician's Drug Program.
 - If a provider wishes to obtain MakenaTM directly and bill through the Physician's Drug Program, it can be ordered from either of the two wholesalers listed on <http://www.makena.com>. The practice will be charged for the drug and can be reimbursed by Medicaid's Physician's Drug Program by submitting a claim for each dose administered. For billing guidelines, refer to the April 2011 Medicaid Bulletin, <http://www.ncdhhs.gov/dma/bulletin/0411bulletin.htm>
- The Division will continue to seek cost-effective alternatives that have evidence supporting prevention of preterm labor.
- The Division questions why the manufacturer of MakenaTM only provides a five-dose vial instead of a single dose vial.

1. Makena. CMCS Informational Bulletin. March 30, 2011.